Sunitinib

• A Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with Specific KIT Exon Mutations Who Were… Recruiting
  2022-503058-37-00 Phase III 8 countries Deciphera Pharmaceuticals Inc.
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca… Recruiting
  2022-501703-27-00 Phase III 14 countries Exelixis Inc.
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting
  2023-509334-19-00 Phase III 4 countries Rayzebio Inc.
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• (Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended
  2022-500637-80-00 Phase III 11 countries Cogent Biosciences Inc.
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended
  2022-503105-38-00 Phase III 8 countries AstraZeneca AB
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended
  2023-506184-34-00 Phase III 11 countries F. Hoffmann-La Roche AG
• A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i… Ended
  2024-513277-52-00 Phase III 5 countries Deciphera Pharmaceuticals Inc.
• Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas Ended
  2024-514776-40-00 Phase I/II 2 countries Asoc Grupo Espanol De Investigacion En Sarcomas
• A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended
  2024-519070-39-00 Phase II 1 country Region Hovedstaden
• Pembrolizumab (MK-3475) plus Epacadostat vs SoC in mRCC Ended
  2024-512016-22-00 Phase III 1 country Incyte Corp.
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 Phase III 7 countries Bristol-Myers Squibb Services Unlimited Company
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 Phase III 7 countries Merck Sharp & Dohme LLC
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 Phase III 13 countries Bristol Myers Squibb International Corporation

Showing 1–17 of 17 trials